key: cord-1041714-dq6ztt51
authors: Annabi, E.; Dupin, N.; Sohier, P.; Garel, B.; Franck, N.; Aractingi, S.; Guégan, S.; Oulès, B.
title: Rare cutaneous adverse effects of COVID‐19 vaccines: a case series and review of the literature
date: 2021-09-02
journal: J Eur Acad Dermatol Venereol
DOI: 10.1111/jdv.17578
sha: 497d916236459e5713b7bdf4649a526cf51e8c7a
doc_id: 1041714
cord_uid: dq6ztt51

Among the vaccines against coronavirus disease 2019 (COVID-19), BNT162b2 from BioNtech-Pfizer and mRNA-1273 from Moderna are mRNA vaccines targeting the Spike protein of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The ChAdOx1 nCoV-19 (AZD1222) from Oxford-AstraZeneca is based on adenovirus expressing the full-length Spike protein. Clinical trials reported different cutaneous adverse events, mainly local injection site reactions, either immediate or delayed on/after 8 days.

Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature Dear Editor, Among the vaccines against coronavirus disease 2019 (COVID-19), BNT162b2 from BioNtech-Pfizer and mRNA-1273 from Moderna are mRNA vaccines targeting the spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The ChAdOx1 nCoV-19 (AZD1222) from Oxford-AstraZeneca is based on adenovirus expressing the full-length spike protein. Clinical trials reported different cutaneous adverse events, mainly local injection site reactions, either immediate or delayed on/after 8 days. [1] [2] [3] We conducted a retrospective observational study among patients referred to the Dermatology Department of Cochin Hospital from January 2021 to April 2021 who presented with skin manifestations induced by COVID-19 vaccines. We excluded patients with immediate and/or delayed local site injection reactions.

We included 8 consecutive cases, 3 men and 5 women, aged from 44 to 80 years, with no history of prior SARS-CoV-2 infection (6 patients had negative SARS-CoV-2 serology) or prior vaccine/drug-induced manifestations (Table 1) . Five, 1 and 2 patients received Pfizer, Moderna or Oxford-AstraZeneca vaccine, respectively. We observed various skin reactions on average 6 days after the first dose: 2 morbilliform exanthemas, diffuse cutaneous erythema, acute generalized exanthematous pustulosis (AGEP), localized oedematous infiltrated plaque, erythematous indurated nodules or livedo racemosa ( Fig. 1 , Table 1 ). Patient 6 developed fixed drug eruption (FDE) 2 days after the second dose without previous history of FDE. No associated systemic manifestation was observed except in Patients 7 and 8 who presented with eosinophilia and fever, respectively. Patient 5 showed a livedo racemosa mimicking erythema ab igne without history of chronic heat exposure. A skin biopsy was performed in 7 patients (Table 1) . Pathological examination showed several different non-specific patterns including association of features of spongiotic and interface dermatitis. Several cases resembled cutaneous drug reactions and 2 had inflammatory infiltrate with numerous eosinophils. In one case, skin biopsy displayed a superficial and deep perivascular and perieccrine lymphocytic infiltrate similar to those of chilblains or chilblain-like lesions. Symptoms subsided within 8-30 days in 6 patients; mild symptoms persisted in 2 cases. Relapse or new skin manifestations occurred in 2 patients following the second dose without worsening of symptoms. Patient 3 relapsed 4 days after the second dose with diffuse cutaneous erythema, also treated with topical corticosteroids and UVB phototherapy. Patient 2 presented with 2 erythematous nodules 4 days after the first dose and chilblains 5 days after the second dose without nodules relapse. A serology performed 2 days after chilblains onset revealed high levels of spike-specific IgG antibodies. Patient 7 presenting with AGEP did not relapse upon second dose of Pfizer vaccine (Table 1) .

Various skin reactions (local site and delayed large local reaction, urticaria, morbilliform purpuric and/or oedematous rash, erythromelalgia, pernio/chilblains, vasculitis) were recently described following Pfizer or Moderna COVID-19 vaccine. [3] [4] [5] We report for the first time vaccine-induced livedo, FDE, AGEP or distant localized oedematous infiltrated plaques or nodules. Relapse occurred in 2 of our patients following the second dose without worsening of symptoms. One relapsing morbilliform rash and 2 cases of recurrent chilblains were described in patients following Moderna and Pfizer vaccine. [6] [7] [8] In McMahon study, 43% of patients with first-dose reactions experienced second-dose recurrence with similar, milder or more severe reactions in 28%, 28% and 45% of cases, respectively. 4 Practitioners should be aware of these side-effects of COVID-19 vaccines which do not require vaccination discontinuation.

Similar COVID-19-associated manifestations have been described in a registry of 716 cases: morbilliform rash (22%), pernio-like lesions (18%), urticaria (16%), retiform purpura (6.4%), and macular erythematous (13%), or vesicular (11%), or papulo-squamous lesions (9.9%). 9,10 One could hypothesize a common immune response directed against the spike RNA or protein inducing vaccine and virus-associated skin lesions.

The patients in this manuscript have given written informed consent to publication of their case details in accordance with French Bioethics Law for retrospective non-interventional research studies. 

Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine

Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study

Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registrybased study of 414 cases

Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 Vaccine: an Italian single-centre case series

Morbilliform rash after administration of Pfizer-BioNTech COVID-19 mRNA vaccine

New-onset chilblains in close temporal association to mRNA-1273 vaccination

BNT162b2 mRNA Covid-19 Vaccine-induced chilblain-like lesions reinforces the hypothesis of their relationship with SARS-CoV-2

The spectrum of COVID-19-associated dermatologic manifestations: an international registry of 716 patients from 31 countries

Cutaneous manifestations in SARS-CoV-2 infection (COVID-19): a French experience and a systematic review of the literature

The authors would like to thank all members of the Dermatology medical team of Cochin Hospital. Of note, Patient 2 case report has previously been published (PMID 34396420).